Priorities for cancer research in low-and middle-income countries: a global perspective
Cancer research currently is heavily skewed toward high-income countries (HICs), with little
research conducted in, and relevant to, the problems of low-and middle-income countries …
research conducted in, and relevant to, the problems of low-and middle-income countries …
Epidemiology and genomics of prostate cancer in Asian men
Prostate cancer is a global health problem, but incidence varies considerably across
different continents. Asia is traditionally considered a low-incidence area, but the incidence …
different continents. Asia is traditionally considered a low-incidence area, but the incidence …
[HTML][HTML] Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019
Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …
prostate cancer have improved outcomes, but there are still many aspects of management …
Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology
JL Mohler, ES Antonarakis, AJ Armstrong… - Journal of the National …, 2019 - jnccn.org
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …
risk stratification and workup, treatment options for localized disease, and management of …
Therapeutic drug monitoring of oral targeted antineoplastic drugs
A Mueller-Schoell, SL Groenland… - European journal of …, 2021 - Springer
Purpose This review provides an overview of the current challenges in oral targeted
antineoplastic drug (OAD) dosing and outlines the unexploited value of therapeutic drug …
antineoplastic drug (OAD) dosing and outlines the unexploited value of therapeutic drug …
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
C Parker, E Castro, K Fizazi, A Heidenreich… - Annals of …, 2020 - annalsofoncology.org
Subclinical prostate cancer is common in men> 50 years. Population-based screening of
men aged between 55 and 69 years, using prostate-specific antigen (PSA) testing, has been …
men aged between 55 and 69 years, using prostate-specific antigen (PSA) testing, has been …
Recent advances in the management of metastatic prostate cancer
Management of metastatic prostate cancer has undergone a revolution over the past decade
with the introduction of several novel agents and repurposing of others. Several clinical trials …
with the introduction of several novel agents and repurposing of others. Several clinical trials …
Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions
regarding the workup of patients with prostate cancer, risk stratification and management of …
regarding the workup of patients with prostate cancer, risk stratification and management of …
Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update
PURPOSE Update all preceding ASCO guidelines on initial hormonal management of
noncastrate advanced, recurrent, or metastatic prostate cancer. METHODS The Expert …
noncastrate advanced, recurrent, or metastatic prostate cancer. METHODS The Expert …
The Lancet Commission on prostate cancer: planning for the surge in cases
Executive summary Prostate cancer is the most common cancer in men in 112 countries,
and accounts for 15% of cancers. In this Commission, we report projections of prostate …
and accounts for 15% of cancers. In this Commission, we report projections of prostate …